comparemela.com

Latest Breaking News On - End to platform - Page 1 : comparemela.com

Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office

Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Pamela-keck
Planegg-martinsried
Unitope-tra
European-patent-office
Prime-standard
European-patent
End-to-platform
Switch-proteins

Medigene AG Expands Its End-To-End Platform By Submitting Three Development Optimization Technology Patents To The European Patent Office

Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term

Planegg/Martinsried, May 21, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE.

Planegg-martinsried
Pamela-keck
Prime-standard
Chief-executive-officer
End-to-platform
Switch-proteins
Programmed-death-ligand

Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond ...

Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for

Pamela-keck
Planegg-martinsried
Prime-standard
Chief-executive-officer
End-to-platform
Switch-proteins
Switch-protein
Programmed-death-ligand

Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Planegg-martinsried
Pamela-keck
Association-for-cancer-immunotherapy
Presents-preclinical-data
Optimal-affinity
Neoantigen-mutant
Prime-standard
Annual-meeting
Chief-executive-officer
End-to-platform
Programmed-death-ligand
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.